Nexalin Technology (NXL) Net Equity Issued and Repurchased (2021 - 2026)
Nexalin Technology (NXL) posted Net Equity Issued and Repurchased of $756000.0 for Q1 2026, down 91.15% on a QoQ basis from $8.5 million in Q3 2022.
Powered by 
Analysis
Nexalin Technology (NXL) Net Equity Issued and Repurchased (2021 - 2026) Analysis & Trends
Nexalin Technology has reported Net Equity Issued and Repurchased for 3 years, with the latest figure at $756000.0 in Q1 2026.
- On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $756000.0 in Q1 2026; TTM through Mar 2026 was $756000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $4.6 million, up 2.88% from the prior year.
- Net Equity Issued and Repurchased was $756000.0 for Q1 2026 at Nexalin Technology, down from $8.5 million in the prior quarter.
- The five-year high for Net Equity Issued and Repurchased was $8.5 million in Q3 2022, with the low at $5100.0 in Q1 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 179.79 Bn | 174.18 Bn | 7.27 Bn | - |
| 2 | Intuitive Surgical | 127.69 Bn | 122.47 Bn | 1.96 Bn | - |
| 3 | Medtronic | 117.23 Bn | 108.41 Bn | 6.34 Bn | 20.00 Mn |
| 4 | Stryker | 103.55 Bn | 100.07 Bn | 4.50 Bn | - |
| 5 | Boston Scientific | 63.24 Bn | 62.70 Bn | 3.85 Bn | - |
| 6 | Edwards Lifesciences | 49.97 Bn | 45.72 Bn | 1.35 Bn | - |
| 7 | Alcon | 32.83 Bn | 31.37 Bn | 1.68 Bn | - |
| 8 | Dexcom | 32.30 Bn | 30.35 Bn | 830.00 Mn | - |
| 9 | Steris | 20.73 Bn | 20.25 Bn | 684.20 Mn | - |
| 10 | Nexalin Technology | 3.44 Mn | 2.44 Mn | 8,897.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 756,000.00 |
| Sep 30, 2022 | 8.54 Mn |
| Mar 31, 2022 | 5,100.00 |
| Dec 31, 2021 | 762,360.00 |